EF Hutton Acquisition Co. I initiated coverage on shares of Replimune Group (NASDAQ:REPL – Get Rating) in a report issued on Thursday, Benzinga reports. The brokerage issued a buy rating and a $60.00 price target on the stock.
REPL has been the topic of several other reports. SVB Leerink increased their price objective on shares of Replimune Group from $30.00 to $34.00 and gave the stock an outperform rating in a report on Wednesday, December 7th. HC Wainwright cut their price objective on shares of Replimune Group from $60.00 to $48.00 and set a buy rating on the stock in a report on Friday, November 4th. BMO Capital Markets raised their price target on shares of Replimune Group from $40.00 to $70.00 and gave the company an outperform rating in a report on Monday, December 12th. Finally, Piper Sandler raised their price target on shares of Replimune Group from $43.00 to $58.00 in a report on Wednesday, December 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $51.57.
Get
Replimune Group alerts:
Replimune Group Trading Down 1.9 %
Shares of REPL stock opened at $25.75 on Thursday. The firm has a market cap of $1.28 billion, a P/E ratio of -9.40 and a beta of 1.69. Replimune Group has a 1-year low of $13.05 and a 1-year high of $28.78. The company has a debt-to-equity ratio of 0.06, a current ratio of 16.12 and a quick ratio of 16.12. The firm's 50-day simple moving average is $22.43 and its 200-day simple moving average is $19.96.
Replimune Group (NASDAQ:REPL – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, equities analysts forecast that Replimune Group will post -2.99 EPS for the current year.
Insider Buying and Selling at Replimune Group
In other Replimune Group news, insider Pamela Esposito sold 15,000 shares of the stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $25.03, for a total value of $375,450.00. Following the completion of the sale, the insider now owns 229,402 shares of the company's stock, valued at $5,741,932.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 23.80% of the stock is owned by corporate insiders.
Institutional Trading of Replimune Group
Several large investors have recently bought and sold shares of REPL. Frazier Life Sciences Management L.P. acquired a new stake in Replimune Group in the first quarter valued at approximately $12,171,000. State Street Corp grew its position in shares of Replimune Group by 36.6% during the first quarter. State Street Corp now owns 1,712,037 shares of the company's stock worth $29,070,000 after buying an additional 458,420 shares in the last quarter. BlackRock Inc. grew its position in shares of Replimune Group by 19.0% during the third quarter. BlackRock Inc. now owns 2,766,371 shares of the company's stock worth $47,775,000 after buying an additional 442,331 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Replimune Group during the second quarter worth approximately $3,781,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Replimune Group by 36.8% during the third quarter. Dimensional Fund Advisors LP now owns 647,356 shares of the company's stock worth $11,178,000 after buying an additional 174,300 shares in the last quarter. Institutional investors and hedge funds own 87.83% of the company's stock.
About Replimune Group
(Get Rating)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Read More
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- Can Chip Gear Maker Lam Continue Its Rally As Earnings Slow?
- Bed Bath & Beyond Stock Crumbles 24% On Possible Bankruptcy News
- Why Is Kraft Heinz Moving Higher
- What will this mean for the Devon Energy stock price this year?
- Nio Stock, Is This The Bottom ?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
